A chromatograph mass spectrometer including: an MS.sup.n−1 analysis setter for setting an analysis execution period for performing an MS.sup.n−1 analysis, an execution time for the analysis and a loop time; an analysis period divider for dividing the analysis period into segments according to a change in number or analysis condition of MS.sup.n−1 analyses to be performed within the same time window; an MS.sup.n analysis setter for performing MS.sup.n−1 analysis to obtain mass spectrum data and for scheduling MS.sup.n analysis, an ion corresponding to a peak satisfying a set condition being designated as a precursor ion; an MS.sup.n analysis execution time allotter for allotting, in each segment, a time period for execution of the MS.sup.n analysis, the time period being calculated by subtracting an event execution time from the loop time; and an analysis executer for repeatedly performing MS.sup.n−1 analysis and MS.sup.n analysis in each segment.

In this application is described a method for preparing nano-VLP composition, thereby permitting purification using chromatography and filtration. The nano-VLP composition has a more uniform size range of filovirus particles, roughly 230 nm diameter, allowing ease of manipulation of the composition, while retaining GP conformational integrity and the antigenic effectiveness of the vaccine. Additionally, the nano-VLP can be lyophilized without loss of nano-VLP structure, or GP immunogenicity. Lyophilized nano-VLP have greatly enhanced thermostability, allowing the creation of a filovirus nano-VLP vaccine without a cold chain requirement.

A process of controlling a sample separation apparatus for separating a fluidic sample includes determining whether the sample separation apparatus is appropriate for carrying out a predefined operation, by simulating the operation of the sample separation apparatus, and taking an action depending on a result of the determining.

The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.

Disclosed is a method of measuring tacrolimus levels in a subject. In exemplary embodiments, the method comprises the steps of: collecting oral fluid from the subject; homogenizing the oral fluid; combining the homogenized oral fluid with a precipitating solvent; separating oral fluid components on a liquid chromatography column by gradient elution with a mixture of a solvent A and a solvent B, wherein the solvent A is about 2 mM ammonium acetate/0.1% (v/v) formic acid in water and solvent B is about 2 mM ammonium acetate/0.1% (v/v) formic acid in MeOH and wherein the amount of solvent B is increased from about 50% (v/v) to about 98% (v/v); and determining amount of tacrolimus in the oral fluid by mass spectrometry.

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

A separation time of an isomer of one or more isomers of a sialylated glycopeptide of a sample is calculated from a peak of a precursor XIC. Product ion intensities of the first group are summed at the separation time producing a first sum and product ion intensities of the second group are summed at the separation time producing a second sum using XICs of the first and second groups. A ratio of the first sum to the second sum is calculated. The ratio at the separation time is compared to predetermined ratio ranges that each corresponds to a combination of a selection from a set of the first linkage and the second linkage taken one or more times. One or more linkages of the sialic acid to the glycan of the isomer are identified from a combination found to match the ratio in the comparison.

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

Atmospheric Triphasic Chromatography (ATC) method comprising the steps introducing a raw plant material containing cannabinoids into a non-polar solvent, dissolving the cannabinoids extracted from the raw plant material in the non-polar solvent and removing the raw plant material to obtain a target solution, performing potency analysis and cannabinoid extract profile analysis of the target solution. The method further includes the steps of preparing an aqueous caustic solution and mixing the target solution with the aqueous caustic solution to obtain a mixture followed by separating the mixture into a first phase solution and a second phase solution, and removing the first phase solution to obtain a caustic target solution and acidifying the caustic target solution to produce precipitation of an undesirable compound in the caustic target solution.

A packing material, wherein to a porous organic polymer carrier including 60 to 95 mol % of a repeating unit derived from glycidyl methacrylate and 5 to 40 mol % of a repeating unit derived from a polyfunctional monomer, one end of at least one alkylene group selected from a linear alkylene group, a cycloalkylene group, and a linear alkylcycloalkylene group, having 4 to 9 carbon atoms is bonded by a glycidyl group derived from glycidyl methacrylate, and an other end of the alkylene group is bonded to any one end of a polyol via an ether bond.